CAJ | 학술논문

目的：探讨恩替卡韦（ETV）联合六味五灵片治疗乙型肝炎肝硬化的疗效。方法将122例乙型肝炎肝硬化患者随机分为对照组60例（口服ETV 0.5 mg/日）和治疗组62例（口服ETV 0.5 mg/日），同时给予六味五灵片1.5 g/次，每日3次口服，疗程均为24周。治疗结束后观察肝功能、HBV DNA低于检测下限的比率、HA、LN、PC-Ⅲ、CIV水平。结果24周观察结束时治疗组的肝功能、HBV DNA低于检测下限的比率以及HA、LN、PC-Ⅲ、CIV指标下降情况均优于对照组，差异有统计学意义（P＜0.01）。结论 ETV联合六味五灵片治疗乙型肝炎肝硬化疗效显著，疗效优于单一用药组，是治疗乙型肝炎肝硬化的有效方法。
목적：탐토은체잡위（ETV）연합륙미오령편치료을형간염간경화적료효。방법장122례을형간염간경화환자수궤분위대조조60례（구복ETV 0.5 mg/일）화치료조62례（구복ETV 0.5 mg/일），동시급여륙미오령편1.5 g/차，매일3차구복，료정균위24주。치료결속후관찰간공능、HBV DNA저우검측하한적비솔、HA、LN、PC-Ⅲ、CIV수평。결과24주관찰결속시치료조적간공능、HBV DNA저우검측하한적비솔이급HA、LN、PC-Ⅲ、CIV지표하강정황균우우대조조，차이유통계학의의（P＜0.01）。결론 ETV연합륙미오령편치료을형간염간경화료효현저，료효우우단일용약조，시치료을형간염간경화적유효방법。
Objective To observe the clinical effect of entecavir (ETV) combined with Liuweiwuling tablets on hepatic cirrhosis.Methods Total of 122 hepatic cirrhosis patients were randomly divided into treatment group and control group: the control group (60 cases) were treated with ETV (0.5 mg/d) for 24 weeks; while the treatment group (62 cases) were treated with Liuweiwuling tablets (1.5 g once, three times a day) and ETV (0.5 mg/d) for 24 weeks. The liver function, HBV DNA and liver ifbrosis markers (HA, LN, PC-Ⅲ, CIV) between the two groups were compared after treatment.Results The liver function, HBV DNA and liver ifbrosis markers (HA, LN, PC-Ⅲ, CIV) in the treatment group were better than those in the control group (P< 0.01).Conclusions ETV combined with Liuweiwuling tablet therapy is an effective treatment and more effective than that with ETV only for patients with hepatic cirrhosis.